# Culture Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/culture-biosciences

- Industry: Healthcare IT
- Headquarters: San Francisco, US
- Website: www.culturebiosciences.com
- Total disclosed funding: $107M
- Latest round: Series B (Oct 14, 2021)
- Investors on record: 11

## About

Culture Biosciences, Inc. is a biotechnology company specializing in cloud-connected bioprocess development technology, offering innovative bioreactor platforms and software solutions to enhance bioprocess workflows for biotechnology and pharmaceutical sectors.Founded in 2016, Culture Biosciences, Inc. operates out of San Francisco, US, focusing on bioprocess development technologies. The company was established with the goal of optimizing bioreactor performance for various applications, and its founder, Will Patrick, has a background in advancing biotechnology solutions. The most recent funding round occurred on October 14, 2021, where the company raised USD 80 mn in Series B funding, led by Northpond Ventures and joined by several other investors. The total amount raised to date is USD 80 mn, with a current company valuation of USD 263.48 mn.Culture Biosciences specializes in cloud-connected bioprocess development technology, primarily through its innovative bioreactor platforms and software solutions. The company’s core offerings include the Culture Console, a cloud-based system designed to optimize bioreactor performance, experiment management, and data analytics, enabling remote design, monitoring, and analysis of cell culture experiments. The bioreactors, including the 250mL bench-scale single-use bioreactor and the 5L single-use bioreactor, serve applications in synthetic biology, protein therapeutics, and viral vector production, targeting biotechnology and pharmaceutical companies.Culture Biosciences generates revenue primarily through subscriptions and partnerships related to its bioprocessing technology. Clients engage with the company through structured transactions, subscribing to the Culture Console software and purchasing bioreactor units as needed. This model allows continuous updates and support, fostering long-term client relationships, with structured transaction models involving direct sales of bioreactor systems and subscription fees for software access, ensuring clients have essential tools for real-time monitoring and data analysis.In October 2021, Culture Biosciences, Inc. raised USD 80 mn in Series B funding led by Northpond Ventures to support the scaling of its 5L and 250L cloud bioreactors, addressing customer demand for larger material quantities for testing and regulatory approvals. The company plans to expand its offerings, including enhancing its bioreactor capabilities, and intends to target new markets in North America, Europe, and Asia to further its reach by the end of 2022.

## Funding rounds

- Series B, Oct 14, 2021, $80M — Cultivian Sandbox Ventures, BoxGroup, E14 Fund, Section 32, Verily Life Sciences LLC, Craft Ventures, The Production Board, Northpond Ventures, Synthesis Capital
- Series A, Feb 18, 2020, $22M — Cultivian Sandbox Ventures, Y Combinator, E14 Fund, Section 32, Verily Life Sciences LLC, The Production Board
- Seed, Feb 12, 2019, $5.5M — Refactor Capital, Section 32, Verily Life Sciences LLC

## Investors

- Refactor Capital (https://capitalatlas.ai/funds/refactor-capital) — Seed
- Section 32 (https://capitalatlas.ai/funds/section-32) — Seed, Series A, Series B
- Verily Life Sciences LLC — Seed, Series A, Series B
- Cultivian Sandbox Ventures (https://capitalatlas.ai/funds/cultivian-sandbox-ventures) — Series A, Series B
- Y Combinator (https://capitalatlas.ai/funds/y-combinator) — Series A
- E14 Fund (https://capitalatlas.ai/funds/e14-fund) — Series A, Series B
- The Production Board (https://capitalatlas.ai/funds/the-production-board) — Series A, Series B
- BoxGroup (https://capitalatlas.ai/funds/boxgroup) — Series B
- Craft Ventures (https://capitalatlas.ai/funds/craft-ventures) — Series B
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series B
- Synthesis Capital — Series B